Back to top

TScan Therapeutics doses first patient in ALLOHA-2 trial

TScan Therapeutics (TCRX) announced that the first patient has been infused with TSC-101 in the pivotal Phase 3 ALLOHA-2 trial. The patient, who wa...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

TScan Therapeutics, Inc. (TCRX)